Peter Hillemanns

25.6k total citations · 1 hit paper
385 papers, 7.2k citations indexed

About

Peter Hillemanns is a scholar working on Epidemiology, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Peter Hillemanns has authored 385 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Epidemiology, 109 papers in Obstetrics and Gynecology and 101 papers in Surgery. Recurrent topics in Peter Hillemanns's work include Cervical Cancer and HPV Research (137 papers), Endometrial and Cervical Cancer Treatments (62 papers) and Photodynamic Therapy Research Studies (35 papers). Peter Hillemanns is often cited by papers focused on Cervical Cancer and HPV Research (137 papers), Endometrial and Cervical Cancer Treatments (62 papers) and Photodynamic Therapy Research Studies (35 papers). Peter Hillemanns collaborates with scholars based in Germany, United States and Netherlands. Peter Hillemanns's co-authors include Philipp Soergel, Matthias Jentschke, Hermann Hertel, Freija Verdoodt, Peter J.F. Snijders, Christian Dannecker, Thilo Dörk, Rüdiger Klapdor, W Michels and Xiuli Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Peter Hillemanns

361 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis

2014 507 citations Peter Hillemanns et al. profile →

Peers

Countries citing papers authored by Peter Hillemanns

Since Specialization

Citations

This map shows the geographic impact of Peter Hillemanns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hillemanns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hillemanns more than expected).

Fields of papers citing papers by Peter Hillemanns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Hillemanns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hillemanns. The network helps show where Peter Hillemanns may publish in the future.

Co-authorship network of co-authors of Peter Hillemanns

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Hillemanns. A scholar is included among the top collaborators of Peter Hillemanns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Hillemanns. Peter Hillemanns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	APL-1702 long-term efficacy and safety for cervical histologic, high-grade squamous intraepithelial lesions: Results from a randomized, phase III, global study 2024 ·Gynecologic Oncology ·(unknown), Fei Chen, Jinghe Lang, Peter Hillemanns, Hongjie Ruan, Xinyan Chen, Zoltán Novàk, Youzhong Zhang, (unknown), Bing Wei, Weiguo Lv, Jing Yu, (unknown), Linn Woelber, (unknown), (unknown), Weihua Song, (unknown), (unknown), (unknown)	1
2	The influence of MRI-based pelvimetric measurements in mother’s choice of delivery in fetal breech position 2024 ·Archives of Gynecology and Obstetrics ·(unknown), (unknown), (unknown), (unknown), Rüdiger Klapdor, Diane M. Renz, (unknown), Constantin von Kaisenberg, Peter Hillemanns, (unknown)	1
3	Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer 2024 ·Geburtshilfe und Frauenheilkunde ·Clemens Tempfer, Tanja Fehm, Dirk Vordermark, (unknown), Matthias W. Beckmann, Dominik Denschlag, Sara Y. Brucker, Markus Wallwiener, Michael Eichbaum, Beyhan Ataseven, Peter Hillemanns, (unknown)	1
4	Innovative operative Konzepte beim Zervixkarzinom 2023 ·Peter Hillemanns, Rüdiger Klapdor, Hermann Hertel	0
5	2022-RA-1597-ESGO Preoperative conization of early cervical carcinoma associated with improved progression free survival 2022 ·International Journal of Gynecological Cancer ·Rüdiger Klapdor, (unknown), Hermann Hertel, Peter Hillemanns	1
6	2022-RA-447-ESGO Efficacy and safety of VB10.16, a therapeutic DNA vaccine specifically targeting antigen-cell presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis 2022 ·International Journal of Gynecological Cancer ·Peter Hillemanns, Kristina Lindemann, Jean‐François Baurain, Paweł Blecharz, Karsten Bruins Slot, Karoline W. Schjetne, (unknown), Agnete B. Fredriksen	1
7	A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial 2022 ·Clinical Cancer Research ·Peter Hillemanns, (unknown), Linn Woelber, Gerd Böhmer, Matthias Jentschke, Karoline W. Schjetne, (unknown), Agnete B. Fredriksen	31
8	Evaluation of FAM19A4/miR124‐2 methylation performance in the management of CIN3 diagnosed pregnant women 2022 ·International Journal of Cancer ·Monika Hampl, Albertus T. Hesselink, Chris J.L.M. Meijer, (unknown), (unknown), (unknown), Carol I. Geppert, Matthias Jentschke, (unknown), Karl Ulrich Petry, Peter Hillemanns	6
9	Classification of high‐grade cervical intraepithelial neoplasia by p16^ink4a, Ki‐67, HPV E4 and FAM19A4/miR124‐2 methylation status demonstrates considerable heterogeneity with potential consequences for management 2021 ·International Journal of Cancer ·(unknown), (unknown), Daniëlle A.M. Heideman, Lise M.A. De Strooper, Renske D.M. Steenbergen, Birgit I. Lissenberg‐Witte, (unknown), Arno Floore, Jesper Bonde, Anja Oštrbenk Valenčak, Mario Poljak, Karl Ulrich Petry, Peter Hillemanns, Nienke E. van Trommel, Johannes Berkhof, Maaike C.G. Bleeker, Chris J.L.M. Meijer	27
10	Sequence Variants in <b><i>TBX6</i></b> Are Associated with Disorders of the Müllerian Ducts: An Update 2019 ·Sexual Development ·(unknown), (unknown), Thomas Römer, Karina Kapczuk, Cordula Schippert, Peter Hillemanns, Peter Wieacker, Susanne Ledig	8
11	Ultrasound versus Clinical Examination to Estimate Fetal Weight at Term 2017 ·Geburtshilfe und Frauenheilkunde ·(unknown), (unknown), Cordula Schippert, (unknown), Peter Hillemanns, I. Staboulidou	14
12	Rare ATAD5 missense variants in breast and ovarian cancer patients 2016 ·Cancer Letters ·Ivana Maleva Kostovska, Jing Wang, Natalia Bogdanova, Peter Schürmann, Sabin Bhuju, Robert Geffers, Matthias Dürst, Clemens Liebrich, Rüdiger Klapdor, Hans Christiansen, Tjoung-Won Park-Simon, Peter Hillemanns, Dijana Plaseska‐Karanfilska, Thilo Dörk	21
13	Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line 2014 ·BMC Cancer ·(unknown), Natalia Bogdanova, Britta Wieland, (unknown), (unknown), Tjoung-Won Park-Simon, Peter Hillemanns, Hans Christiansen, Thilo Dörk	11
14	Lymphedema of the Breast as a Symptom of Internal Diseases or Side Effect of mTor Inhibitors 2012 ·Lymphatic Research and Biology ·Ulrike E. Hille, Philipp Soergel, Liza Makowski, Thilo Dörk, Peter Hillemanns	10
15	Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany 2010 ·SHILAP Revista de lepidopterología ·Alexander Krämer, Uwe Siebert, Karl Ulrich Petry, Peter Hillemanns, Jutta Engel, Jürgen Wasem, Thomas Mittendorf, Pamela Aidelsburger, Katharina Lang, Gaby Sroczynski, Petra Schnell‐Inderst, Nikolai Mühlberger	10
16	The German Cervical Cancer Screening Model: development and validation of a decision-analytic model for cervical cancer screening in Germany 2006 ·European Journal of Public Health ·Uwe Siebert, Gaby Sroczynski, Peter Hillemanns, Jutta Engel, Roland Stabenow, Christa Stegmaier, Kerstin Voigt, Bernhard Gibis, D. Hölzel, Sue J. Goldie	48
17	Episiotomy and perineal tears presumed to be imminent: randomized controlled trial 2004 ·Acta Obstetricia Et Gynecologica Scandinavica ·Christian Dannecker, Peter Hillemanns, Alexander Strauß, Uwe Hasbargen, H. Hepp, C. Anthuber	58
18	Routine Cervical Cerclage in Higher Order Multiple Gestation — Does It Prolong the Pregnancy? 2002 ·Twin Research ·Alexander Strauß, (unknown), (unknown), Christian Dannecker, Peter Hillemanns, (unknown)	15
19	Epidemiology and diagnostic procedures of cervical intraepithelial neoplasia - Is the current concept of screening and diagnostic triage strategy still valid? 1998 ·Gyn�kologisch-geburtshilfliche Rundschau ·Peter Hillemanns, Christian J. Thaler, Rainer Kimmig	4
20	Localization of cellular retinoid-binding proteins in human cervical intraepithelial neoplasia and invasive carcinoma. 1992 ·PubMed Central ·Peter Hillemanns, (unknown), John P. Koulos, David A. Talmage, Thomas C. Wright	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact